glp-1 pancreatitis class action in west virginia Agonists and Risk: Reassessing an Old Concern with New Evidence GLP-1 receptor agonists and the

Nausea, vomiting, diarrhea, and constipation affect a significant percentage of patients, particularly during dose titration

doi:10.3892/or_00000144

7 Despite the growing evidence of the CV benefits of GLP-1 RAs and dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists/GLP-1 RAs in T2D patients and their inclusion in guidelines, lack of awareness of the CV benefits of GLP-1 RAs and dual GIP/GLP-1 RAs, clinical inertia, resistance to injectable medications and concerns about treatment costs have hindered the widespread adoption of GLP-1 RAs

Hoffmann-La Roche Ltd (Switzerland) Merck & Co., Inc